Abstract.
Adult rat ventricular cardiomyocytes contain α1A- and α1B-adrenoceptors (ARs, 20%:80%, assessed by [3H]prazosin binding). We studied which α1-AR subtype mediates noradrenaline (NA)-induced increase in rate of protein synthesis, and which signalling pathway is involved. NA (10–9–10–4 M) concentration-dependently increased inositol phosphate (IP) formation (pEC50-value=6.1±0.1, n=5) and protein synthesis (assessed as [3H]phenylalanine incorporation; pEC50-value=6.6±0.1, n=6). NA-induced IP-formation was partly inhibited by the α1B-AR antagonist chloroethylclonidine (CEC, 30 µM; 33±9% inhibition, n=5); following CEC-treatment the α1A-AR-selective 5-methyl-urapidil (5-MU) inhibited NA-induced IP-formation with a pK i-value of 9.2±0.2 (n=6); the α1D-AR-selective BMY 7378 was only a weak antagonist (pK i-value <7). NA-induced increase in protein synthesis was insensitive to CEC whereas 5-MU inhibited it with a pK i-value of 9.1±0.2 (n=6). NA (1 µM)-induced increase in protein synthesis was inhibited by the protein kinase C (PKC) inhibitor bisindolylmaleimide (IC50-value: 206 nM), the PI 3-kinase inhibitors wortmannin (IC50=3.4 nM) and LY 294002 (IC50=10 µM), and p70s6-kinase inhibitor rapamycin (IC50=123 pM) but not by the p38 MAP-kinase inhibitor SB 203580 (10 µM) or the MEK-inhibitor PD 98059 (25 µM). Moreover, 5-MU (30 nM) but not CEC inhibited NA-induced activation of p70s6-kinase. We conclude that, in adult rat cardiomyocytes, α1A- and α1B-AR mediate NA-induced IP-formation but only α1A-ARs mediate increase in protein synthesis. α1A-AR-mediated increase in protein synthesis involves activation of a PKC, PI 3-kinase and p70s6-kinase but not of ERK- or p38 MAP-kinase.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Pönicke, K., Schlüter, KD., Heinroth-Hoffmann, I. et al. Noradrenaline-induced increase in protein synthesis in adult rat cardiomyocytes: involvement of only α1A-adrenoceptors. Naunyn-Schmied Arch Pharmacol 364, 444–453 (2001). https://doi.org/10.1007/s002100100469
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s002100100469